We describe heparin/diazeniumdiolate conjugates that generate nitric oxide (NO) at physiological pH. Like the heparin from which they were prepared, they inhibit thrombin-induced blood coagulation. Unlike heparin, they can also inhibit and reverse ADP-induced platelet aggregation (as expected for an NO-releasing agent), suggesting potential utility as dual-action antithrombotics. Published by Elsevier Science Ltd.
Bibliographical noteFunding Information:
The technical assistance of Steven Burris is greatly appreciated. This project was funded in part through NIH grant GM-56991 and by the National Cancer Institute under contract NO1-CO-56000.